| 摘要: |
| 目的：探讨丙卡特罗联合孟鲁司特治疗儿童支气管哮喘的疗效及其对趋化素样因子-1（CKLF-1）、嗜酸粒细胞阳离子蛋白（ECP）、白细胞介素-12（IL-12）、白细胞介素-13（IL-13）水平及肺功能的影响。方法：选取我院2017年8月至2019年4月收治的支气管哮喘患儿94例，按随机数字表法分为对照组和观察组各47例，两组患儿均接受抗炎、平喘、支气管扩张等常规治疗，对照组给予孟鲁司特钠片，观察组在对照组治疗基础上给予丙卡特罗治疗，比较两组治疗后的临床疗效，分析治疗前后两组CKLF-1、ECP、IL-12、IL-13水平及肺功能变化情况。结果：观察组总有效率高于对照组（P<0.05）。观察组不良反应发生率（8.51%）与对照组（4.26%）比较差异无统计学意义（P>0.05）。治疗前，两组CKLF-1、ECP、IL-12、IL-13水平及肺功能指标比较差异无统计学意义（P>0.05）；治疗后观察组IL-12、第１秒用力呼气容积（FEV1）、第１秒用力呼气量占用力肺活量比值（FEV1/FVC）、呼气峰流速值（PEF）、呼气高峰流量（PEFR）水平高于对照组，CKLF-1、ECP、IL-13水平低于对照组（P<0.05）。结论：丙卡特罗联合孟鲁司特治疗儿童支气管哮喘可改善肺功能，调节CKLF-1、ECP、IL-12、IL-13表达水平，提高临床疗效，且不增加不良反应。 |
| 关键词: 丙卡特罗 孟鲁司特 支气管哮喘 趋化素样因子-1 嗜酸粒细胞阳离子蛋白 |
| DOI：doi:10.13407/j.cnki.jpp.1672.108X.2021.03.007 |
|
| 基金项目: |
|
| Efficacy of Procaterol Combined with Montelukast in the Treatment of Bronchial Asthma in Children |
| Zheng Mei, Wen Xiaomin, Wang Feng |
| (Xiangyang No. 1 Prople’s Hospital, Affiliated Hospital of Hubei University of Medicine, Hubei Xiangyang 441000, China) |
| Abstract: |
| Objective: To probe into the efficacy of procaterol combined with montelukast in the treatment of bronchial asthma in children and its effects on chemokine-like factor-1 (CKLF-1), eosinophil cationic protein (ECP), interleukin-12 (IL-12), interleukin-13 (IL-13) and lung function. Methods: Totally 94 children with bronchial asthma admitted into our hospital from Aug. 2017 to Apr. 2019 were extracted to be divided into the control group and the observation group via the random number table, with 47 cases in each group. Both groups received conventional treatment such as anti-inflammatory, asthma relieving and bronchiectasia treatment. The control group was given montelukast sodium tablets, while the observation group received procaterol on the basis of the control group. The clinical efficacy of two groups were compared. The levels of CKLF-1, ECP, IL-12, IL-13 and changes of lung function in two groups were analyzed before and after treatment. Results: The total effective rate of the observation group was higher than that of the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the observation group (8.51%) and the control group (4.26%, P>0.05). Before treatment, there was no significant difference in the levels of CKLF-1, ECP, IL-12, IL-13 and lung function indexes between two groups (P>0.05). After treatment, the levels of IL-12, forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory flow (PEF) and peak expiratory flow rate (PEFR) in the observation group were higher than those in the control group, while the levels of CKLF-1, ECP and IL-13 were lower than those in the control group (P<0.05). Conclusion: Procatechol combined with montelukast in the treatment of children with bronchial asthma can improve the lung function, regulate the expression levels of CKLF-1, ECP, IL-12 and IL-13, and improve the clinical efficacy without increasing adverse drug reactions. |
| Key words: procaterol montelukast bronchial asthma chemokine-like factor-1 eosinophils cationic protein |
